Somato® (Phytomelatonin) Versus Synthetic Melatonin and Placebo on Sleep Quality
25 juni 2026 uppdaterad av: Nutraland USA, Inc.
Sleep Solutions in Focus: A Randomized Comparison of Phytomelatonin (Somato®), Synthetic Melatonin, and Placebo
This study examines the effects of a plant-based phytomelatonin supplement compared to synthetic melatonin and placebo in adults with suboptimal sleep quality.
The research uses a randomized, double-blind, placebo-controlled, three-arm clinical trial design.
The primary aim is to determine whether phytomelatonin improves sleep outcomes compared to placebo and whether it matches or exceeds synthetic melatonin.
Participants will be randomly assigned to receive 2 mg phytomelatonin, 10 mg synthetic melatonin, or an inactive placebo.
Each participant will take one capsule nightly for 28 days.
Objective sleep metrics will be captured continuously using the Oura Ring wearable device.
Subjective outcomes will be measured at baseline and post-intervention using validated surveys such as the Pittsburgh Sleep Quality Index and the SF-36.
Weekly visual analog scales will assess morning grogginess.
Safety, tolerability, and user experience differences between groups will also be evaluated.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
244
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Delaware
-
Wilmington, Delaware, Förenta staterna, 19808
- N/A Decentralized Trial - address for CRO headquarters, not the study location
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Ja
Beskrivning
Inclusion Criteria:
- Device Compliance: Willingness to consistently wear an Oura Ring Gen3 and maintain an active membership throughout the study duration.
- Baseline Sleep Score: A baseline Oura sleep score of less than 75, indicating sub-optimal sleep quality.
- Oura Ring Usage History: Demonstrated at least 80% adherence to Oura Ring use during the 30 days prior to enrollment.
- Health and Supplement Stability: No significant changes in dietary supplement use or medical history within the past 30 days, to ensure stability in baseline physiological and health conditions.
Exclusion Criteria:
- Current or recent use (within the past 30 days) of any sleep-promoting dietary supplement.
- Current or recent use (within the past 30 days) of any sleep-promoting medications, whether prescription or over-the-counter.
- Pregnant or breastfeeding women will be excluded from the study.
- Substance Use Disorder: Individuals with a history of drug or alcohol dependency who have not maintained sobriety for a minimum of the past 12 months.
- Severe Medical Conditions: Presence of severe or unstable medical conditions that may interfere with study participation or outcomes.
- Use of Mood-Affecting Medications: Use of any medications known to significantly influence mood, circadian rhythms, or melatonin pathways.
- Sensitivity to Nightshades: Known sensitivity or allergy to nightshade plants, including tomatoes, due to the nature of the study intervention.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: Placebo
|
Placebo kapsel
|
|
Aktiv komparator: Synthetic Melatonin
Synthetic Melatonin - 10mg
|
10mg Synthetic Melatonin capsule
Andra namn:
|
|
Experimentell: Somato®
Somato® Phytomelatonin 2mg
|
2mg Phytomelatonin (plant-based melatonin from tomatoes) capsule
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from Baseline Pittsburgh Sleep Quality Index (PSQI) Global Score at Day 28
Tidsram: Baseline (Day 0) and Day 28
|
The PSQI is a self-administered questionnaire used to measure sleep quality and disturbances over a 1-month time interval.
The questionnaire consists of 19 individual items, creating 7 component scores that are summed to yield one global score.
The total score ranges from 0 to 21, where lower scores denote better sleep quality.
|
Baseline (Day 0) and Day 28
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from Baseline Objective Sleep Efficiency at Day 28
Tidsram: Baseline (Day 0) and Day 28
|
Sleep efficiency percentage as measured continuously via the Oura Ring 3.0 wearable device.
Calculated as the percentage of time in bed spent asleep.
|
Baseline (Day 0) and Day 28
|
|
Change from Baseline Objective Total Sleep Time at Day 28
Tidsram: Baseline (Day 0) and Day 28
|
Total accumulated sleep duration in minutes per night, measured continuously via the Oura Ring 3.0 wearable device.
|
Baseline (Day 0) and Day 28
|
|
Change from Baseline Objective Sleep Latency at Day 28
Tidsram: Baseline (Day 0) and Day 28
|
The time taken to transition from full wakefulness to sleep in minutes, measured continuously via the Oura Ring 3.0 wearable device.
|
Baseline (Day 0) and Day 28
|
|
Change from Baseline Objective REM Sleep Duration at Day 28
Tidsram: Baseline (Day 0) and Day 28
|
Total duration of Rapid Eye Movement (REM) sleep in minutes per night, measured continuously via the Oura Ring 3.0 wearable device.
|
Baseline (Day 0) and Day 28
|
|
Change from Baseline Objective Deep Sleep Duration at Day 28
Tidsram: Baseline (Day 0) and Day 28
|
Total duration of Deep (slow-wave) sleep in minutes per night, measured continuously via the Oura Ring 3.0 wearable device.
|
Baseline (Day 0) and Day 28
|
|
Change from Baseline Objective Light Sleep Duration at Day 28
Tidsram: Baseline (Day 0) and Day 28
|
Total duration of Light sleep in minutes per night, measured continuously via the Oura Ring 3.0 wearable device.
|
Baseline (Day 0) and Day 28
|
|
Change from Baseline Nocturnal Resting Heart Rate at Day 28
Tidsram: Baseline (Day 0) and Day 28
|
Average overnight resting heart rate in beats per minute (bpm), measured continuously via the Oura Ring 3.0 wearable device.
|
Baseline (Day 0) and Day 28
|
|
Change from Baseline Nocturnal Heart Rate Variability (HRV) at Day 28
Tidsram: Baseline (Day 0) and Day 28
|
Overnight Heart Rate Variability (HRV) in milliseconds (ms) using the rMSSD (Root Mean Square of Successive Differences) method, measured continuously via the Oura Ring 3.0 wearable device.
|
Baseline (Day 0) and Day 28
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from Baseline 36-Item Short-Form Health Survey (SF-36) Score at Day 28
Tidsram: Baseline (Day 0) and Day 28
|
The SF-36 is a multi-purpose, short-form health survey.
Scored from 0 to 100, where higher scores mean better health outcomes.
|
Baseline (Day 0) and Day 28
|
|
Change from Baseline Morning Functioning Visual Analogue Scale (VAS) Composite Score at Day 28
Tidsram: Baseline (Day 0) and Day 28
|
Morning functioning assessed via a 6-item questionnaire utilizing a Visual Analogue Scale.
Items measure dimensions such as grogginess, sleepiness, difficulty concentrating, alertness, feeling refreshed, and readiness for the day.
Individual items are directionally aligned and averaged to create a composite score ranging from 1 to 10, where higher scores represent better morning functioning.
|
Baseline (Day 0) and Day 28
|
|
Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) Sub-component Scores at Day 28
Tidsram: Baseline (Day 0) to Day 28
|
The Pittsburgh Sleep Quality Index (PSQI) is a 19-item self-reported questionnaire that evaluates subjective sleep quality changes from baseline.
Each component is scored on a Likert scale ranging from 0 to 3, where higher scores reflect a greater severity of sleep difficulties within that specific domain.
|
Baseline (Day 0) to Day 28
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Samarbetspartners
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
13 januari 2026
Primärt slutförande (Faktisk)
17 april 2026
Avslutad studie (Faktisk)
17 april 2026
Studieregistreringsdatum
Först inskickad
3 februari 2026
Först inskickad som uppfyllde QC-kriterierna
22 juni 2026
Första postat (Faktisk)
25 juni 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
30 juni 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
25 juni 2026
Senast verifierad
1 juni 2026
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- BB2512MD-154
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
OBESLUTSAM
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .